Vinge has advised the international private equity firm PSG Equity in connection with its investment in Visit Group International AB ("Visit Group")

Headquartered in Gothenburg, Sweden, Visit Group is a market leader in the Nordics within hospitality and travel technology, providing collaborative commerce software to in-destination experience vendors, including lodgings, day tours and attractions, mountain resorts, ferry operators, amusement parks and activity vendors. As of August 2023, the company serves more than 2,200 customers in over 25 countries. Visit Group’s multiple software solutions create a unique ecosystem that helps hospitality and travel providers package, sell, distribute, and deliver guest experiences.

PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 130+ companies and facilitated over 470+ add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams.

With PSG’s support, Visit Group will invest to help accelerate both organic and inorganic growth across the region by broadening the range and depth of solutions offered to its customers. The transaction marks PSG’s first platform investment in Sweden and Norway.

Vinges team mainly consisted of Christina Kokko, Samra Tesser, Gustav Wahlberg and Jonatan Stentorp (M&A), Axel Lennartsson (IP), Gulestan Ali (Employment), Martin Boström (Agreements), Carla Zachariasson (IT), Arthur Kinski (GDPR), Maja Höglund (Compliance), Karl-Gustaw Tobola and August Ahlin (Financing), Frida Ställborn (Real Property) as well as Emma Emsjö and Johanna Engström (Transaction Support Coordinators).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025